Sandoz begins U.S. Phase III trial of biosimilar epoetin alfa

Novartis AG (NYSE:NVS; SIX:NOVN) said its Sandoz unit began a U.S. Phase III trial of a biosimilar version of anemia drug epoetin alfa that is intended to support FDA approval. The double-blind trial ...